国際・国内特許データベース検索
このアプリケーションの一部のコンテンツは現在ご利用になれません。
この状況が続く場合は、次のお問い合わせ先までご連絡ください。フィードバック & お問い合わせ
1. (EP2140871) SUSPENSION FOR VISUALIZATION OF TRANSPARENT TISSUE IN EYE
注意: このテキストは、OCR 処理によってテキスト化されたものです。法的な用途には PDF 版をご利用ください。
Claims

1. An ocular transparent tissue-visualizing suspension comprising, in an aqueous medium, fine particles of a biodegradable macromolecular compound and at least one salt selected from the group consisting of salts of divalent metals and salts of trivalent metals, wherein the composition is designed to be infused into the eye to be brought into contact with transparent tissues of the eye to enhance the visibility thereof.
  2. The ocular transparent tissue-visualizing suspension according to claim 1, wherein the fine particles of a biodegradable macromolecular compound are those one g of which cannot completely be dissolved in less than 30 mL of water within 30 minutes at 20 °C.
  3. The ocular transparent tissue-visualizing suspension according to claim 1 or 2, wherein the biodegradable macromolecular compound is selected from the group consisting of polylactic acid, polyglycolic acid, and copoly(lactic acid/glycolic acid).
  4. The ocular transparent tissue-visualizing suspension according to one of claims 1 to 3, wherein the concentration of the salt of a trivalent metal is 0.01-1 w/v% and/or the concentration of the salt of a divalent metal is 0.1-1 w/v%.
  5. The ocular transparent tissue-visualizing suspension according to one of claims 1 to 4, wherein the salt of a trivalent metal is selected from aluminum salts, and iron salts, and wherein the divalent salt is selected from magnesium salts, calcium salts, and zinc salts.
  6. The ocular transparent tissue-visualizing suspension according to one of claims 1 to 5, wherein the salt of a trivalent metal is aluminum potassium sulfate.
  7. The ocular transparent tissue-visualizing suspension according to one of claims 1 to 6, wherein the salt of a divalent metal is magnesium chloride or calcium chloride.
  8. The ocular transparent tissue-visualizing suspension according to one of claims 1 to 7, further comprising a polyvinyl-based compound, which may be polyvinylpyrrolidone or polyvinylalcohol, and/or a polyol.
  9. The ocular transparent tissue-visualizing suspension according to claim 8, wherein the polyvinyl-based compound is polyvinylpyrrolidone and the polyol is mannitol.
  10. The ocular transparent tissue-visualizing suspension according to one of claims 1 to 9, wherein content of the fine particles of the biodegradable macromolecular compound is 0.005-10 w/v% .
  11. A method for preparation of an ocular transparent tissue-visualizing suspension comprising the steps of

providing a solid preparation comprising fine particles of a biodegradable macromolecular compound,

providing an aqueous solution containing at least one salt selected from the group consisting of salts of trivalent metals and salts of divalent metals, wherein the concentration of the salt of a trivalent metal is not less than 0.01 w/v%, and/or wherein the concentration of the salt of a divalent metal is not less than 0.1 w/v%, and

suspending the fine particles in the aqueous solution.


  12. The method for preparation of an ocular transparent tissue-visualizing suspension according to claim 11, wherein the fine particles of a biodegradable macromolecular compound are those one g of which cannot completely be dissolved in less than 30 mL of water within 30 minutes at 20 °C.
  13. The method for preparation of an ocular transparent tissue-visualizing suspension according to claim 11 or 12, wherein the solid preparation and/or the aqueous solution further comprises at least one compound selected from the group consisting of polyvinyl-based compounds and polyols.
  14. A method for preparation of an ocular transparent tissue-visualizing suspension comprising the steps of

providing a solid preparation comprising fine particles of a biodegradable macromolecular compound and at least one salt selected from the group consisting of salts of trivalent metals and salts of divalent metals, and

forming a suspension by mixing the solid preparation with an aqueous medium so that the concentration of the salt of a trivalent metal is not less than 0.01 w/v% and/or the concentration of the salt of a divalent metal is not less than 0.1 w/v%.


  15. The method for preparation of an ocular transparent tissue-visualizing suspension according to claim 14, wherein the fine particles of a biodegradable macromolecular compound are those one g of which cannot completely be dissolved in less than 30 mL of water within 30 minutes at 20 °C.
  16. The method for preparation of an ocular transparent tissue-visualizing suspension according to claim 14 or 15, wherein the solid preparation and/or the aqueous medium contains at least one compound selected from the group consisting of polyvinyl-based compounds and polyols.
  17. An ophthalmic transparent tissue-visualizing preparation comprising a solid preparation comprising fine particles of a biodegradable macromolecular compound and an aqueous medium, separately and kept from contact with each other, wherein the aqueous medium and/or the solid preparation contains a salt of a trivalent metal and/or a salt of divalent metal so that a suspension obtained by mixing the solid preparation with the aqueous medium contains the salt of the trivalent metal at a concentration of not less than 0.01 w/v% and/or the salt of the divalent metal at a concentration of not less than 0.1 w/v%.
  18. The ophthalmic transparent tissue-visualizing preparation according to claim 17, wherein the fine particles of a biodegradable macromolecular compound are those one g of which cannot completely be dissolved in less than 30 mL of water within 30 minutes at 20 °C.
  19. The ophthalmic transparent tissue-visualizing preparation according to claim 17 or 18, wherein the solid preparation and/or the aqueous medium contains at least one compound selected from the group consisting of polyvinyl-based compounds and/or polyols.
  20. The ophthalmic transparent tissue-visualizing preparation according to one of claims 17 to 19, wherein the content of the fine particles of a biodegradable macromolecular compound in the suspension is 0.005-10 w/v%.
  21. The ophthalmic transparent tissue-visualizing preparation according to one of claims 17 to 20, wherein the solid preparation and the aqueous medium are contained in a single means for mixing and discharging them.
  22. A method for enhancing visibility of transparent tissues of the eye comprising infusing the suspension according to one of claims 1 to 10 into the eye to bring the suspension into contact with the transparent tissues of the eye.